Pliant Therapeutics, Inc.
corporate_fare Company Profile
Pliant Therapeutics, Inc. (NASDAQ:PLRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for PLRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 15 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for PLRX spans 10-Q, 8-K, DEF 14A, S-3.
Recent high-impact activity:
- Pliant Q3 Loss Narrows to $24.4M; Discloses Nasdaq $1.00 Bid-Price Deficiency
- Pliant Q2 Loss Narrows, Cash Runway Extended to H2 2028; FORTIFY Trial Enrollment Ahead of Schedule
- Pliant Therapeutics Reports Strong Q2: Narrows Loss, Extends Cash Runway, Advances Oncology Program
- Pliant Q2 Loss Narrows, Cash Runway Extended to H2 2028 as Oncology Pipeline Advances
- Q1 Net Loss Narrows Significantly, Cash Burn Halves Amid Strategic Refocus
Financial Snapshot
Short Interest & Short Volume
16.20 days to coverFINRA reported short interest of 4,881,070 shares in PLRX as of the October 30, 2026 settlement, a 5.3% increase from the prior period — about 16.2 days to cover at its recent average daily volume. On November 19, 2026, 30.5% of PLRX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.